IGF1 E3R Human
Insulin-Like Growth Factor-1.
Greater than 95% as determined by SDS-PAGE.
Description
IGF1 E3R Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 77 amino acids (Gly49-Ala118) and having a molecular mass of 8.6kDa.
IGF1 E3R Human is fused to a 6 a.a his tag at C-Terminus and is purified by proprietary chromatographic techniques.
Product Specs
Insulin-Like Growth Factor-1.
MGPRTLCGAE LVDALQFVCG DRGFYFNKPT GYGSSSRRAP QTGIVDECCF RSCDLRRLEM YCAPLKPAKS AHHHHHH.
Product Science Overview
Insulin-Like Growth Factor-1 (IGF-1) is a protein that plays a crucial role in growth and development, particularly during childhood. It is structurally similar to insulin and has significant effects on cell growth, differentiation, and survival. The mutant E3R variant of IGF-1 is a specific form that has been engineered for research and therapeutic purposes.
The IGF-1 E3R mutant is a recombinant protein produced in Escherichia coli (E. coli). It is a single, non-glycosylated polypeptide chain consisting of 77 amino acids, with a molecular mass of approximately 8.6 kDa . This variant includes a mutation at the E3 position, where glutamic acid (E) is replaced by arginine ®. Additionally, it is fused to a six amino acid histidine tag at the C-terminus to facilitate purification through chromatographic techniques .
IGF-1 is involved in various physiological processes, including:
- Cell Growth and Differentiation: IGF-1 promotes the proliferation and differentiation of various cell types, including muscle, bone, and nerve cells.
- Metabolic Regulation: It enhances insulin sensitivity and plays a role in glucose metabolism.
- Tissue Repair and Regeneration: IGF-1 is critical for tissue repair and regeneration, particularly in muscle and bone tissues.
Recombinant human IGF-1, including the E3R mutant, has been explored for several therapeutic applications:
- Diabetes Management: IGF-1 has been shown to increase insulin sensitivity and improve glycemic control in patients with type II diabetes . It reduces blood glucose levels and decreases serum insulin concentrations, thereby improving overall metabolic control.
- Growth Disorders: IGF-1 is used to treat children with severe primary IGF-1 deficiency, which can result from genetic mutations affecting the growth hormone (GH) receptor or post-GH receptor signaling pathways . It has been approved by regulatory agencies for this purpose and has shown significant improvements in growth rates.
- Muscle Wasting and Degenerative Diseases: IGF-1 is being investigated for its potential to treat muscle wasting conditions and degenerative diseases due to its anabolic effects on muscle tissue.
The E3R mutant of IGF-1 is valuable in research settings for studying the protein’s structure-function relationships and its interactions with receptors. It provides insights into the mechanisms underlying IGF-1’s biological activities and helps in the development of targeted therapies for various diseases.
